Loading

Mini Review Open Access
Volume 6 | Issue 4 | DOI: https://doi.org/10.33696/cancerimmunol.6.094

Phosphopeptide Neoantigens as Emerging Targets in Cancer Immunotherapy

  • 1Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA
  • 2Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA
+ Affiliations - Affiliations

Corresponding Author

Michelle Krogsgaard, Michelle.Krogsgaard@nyulangone.org

Received Date: August 28, 2024

Accepted Date: September 26, 2024

Abstract

Protein post-translational modifications play a vital role in various cellular events essential for maintaining cellular physiology and homeostasis. In cancer cells, aberrant post-translational modifications such as glycosylation, acetylation, and phosphorylation on proteins can result in the generation of antigenic peptide variants presented in complex with MHC molecules. These modified peptides add to the class of tumor-specific antigens and offer promising avenues for targeted anti- cancer therapies. In this review, we focus on the role of phosphorylated peptides (p-peptides) in cancer immunity. We discuss the mechanisms by which the phosphorylated moiety modifies the structural features and binding properties of p-peptides with MHC, compared to their non-phosphorylated counterparts. Additionally, we review recent work on how the HLA-B*07-specific p-peptide, pMLL747–755, interacts with its cognate TCR. Altogether, p-peptides are emerging as a novel class of tumor- specific antigens, expanding the range of targets in cancer immunotherapy.

Keywords

Post-translational modifications, Immunopeptidome, Phosphorylation, Neoantigens, Immune checkpoint blockade therapies

Author Information X